30 closest matches · ranked by relevance
Pneumococcal Infections
Primary: TIV Comparisons: Percentage of Participants Achieving at Least a 4-fold Increase in the Titer of the Standard Hemagglutination Inhibition Assay (HAI) — 80.3; 78.6; 58.0…
Pneumococcal Infections
Primary: Percentage of Participants With Solicited Injection-site Adverse Events Following V114 or Prevnar 13™ — 15.1; 14.0; 75.8; 68.8 Percentage of Participants
Pulmonary Disease, Chronic Obstructive
Primary: Serotype Opsonization Titers — 10.85; 12.63; 132.51; 908.23 titers
Pneumococcal Infection
Primary: Percentage of Participants With Solicited Injection-site Adverse Events (AEs) From Day 1 Through Day 5 Post-vaccination — 9.1; 25.4; 51.8; 78.5 Percentage of participants
Pneumococcal Infections
Primary: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination 1 — 146; 104; 200; 353 titer
Pneumococcal Infections
Primary: Immune Responses — 1.95; 1.69; 1.22; 0.78 ug/mL
Pneumonia, Pneumococcal · Pneumococcal Infections · 13-valent Pneumococcal Vaccine
Primary: Number of Participants With First Episode of Confirmed Vaccine-type Community-acquired Pneumonia (VT-CAP) — 49; 90 participants — p=0.0006
Pneumococcal Infections
Primary: Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination — 120; 84; 88; 89 titer
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Primary: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 13 Pneumococcal Serotypes — 75; 83; 41; 49 titer
Pneumococcal Vaccines
Primary: Solicited Local Adverse Events (AEs) — 0; 0; 0; 0 events
Pneumococcal Infection
Primary: Number of Participants Reporting Solicited Local and Systemic Adverse Events — 148; 153; 187; 213 participants
Pneumococcal Infection
Primary: Number of Participants With Innate Immunity Signatures That Correlate With the Quality of Antibodies After PNEUMOVAX and PREVNAR - Monocyte Module M4.15 — 1; 2; 0; 2…
Pneumonia, Bacterial · Healthy Volunteers · Pneumococcal Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), [Stage 1, Group 1] — 11; 5; 5; 5 Participants
Community Acquired Pneumonia (CAP)
Primary: Number of Participants Categorized as Cases and Controls to Determine Vaccine Effectiveness (VE) of PCV13 Against Hospitalized VT CAP: Overall — 105; 1407 Participants…
Pneumococcal Vaccines
Primary: Percentage of Subjects Reporting Solicited Local Reactions Within 7 Days After Vaccination (Redness, Swelling, and Pain at Injection Site) in Each Age Group — 66.8…
Infections, Streptococcal · Streptococcus Pneumoniae
Primary: Person Year Rate as Regards Subjects With Culture-confirmed IPD Due to Any of the 10 Pneumococcal Vaccine Serotypes. In Children Starting Vaccination Within 7 Months of…
Invasive Pneumococcal Disease
Primary: Percentage of Participants Achieving a Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to ( ≥) 0.35 Micrograms Per…
Pneumococcal Vaccines
Primary: Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination — 42.3; 62.7; 37.7; 48.0 percentage of participants
Asthma
Primary: Immunogenicity of Pneumococcal Vaccination — 0.05; 0.05 [µg/ml]
Infections, Streptococcal
Primary: Number of Subjects Reporting Rectal Temperature Above (>) 39.0 Degrees Celsius (°C) — 31; 6; 30; 13 Participants
Pneumococcal Immunization
Primary: Geometric Mean Titers (GMTs) of Pneumococcal Serotypes Using Serotype-Specific MOPA — 128; 127; 158; 254 Titer
Vaccines, Pneumococcal
Primary: Percentage of Participants Achieving Predefined Meningococcal C Serum Bactericidal Assay (SBA) Titer of ≥ 1:8, and a Predefined Antibody Level for Diphtheria in 13vPnC…
Vaccines, Pneumococcal
Primary: Percentage of Participants Achieving Antibody Level ≥0.35 μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series — 98.2; 98.2; 77.5; 87.1…
Pneumococcal Vaccines
Primary: Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group — 56.3; 81.3; 81.3; 93.8 percentage of participants
Infants
Primary: Number of Participants With Adverse Reactions — 432; 3 Participants
Adult Not Younger Than 65 Years
Primary: Number of Participants With Adverse Reactions — 80; 1 Participants
Community Acquired Pneumonia
Primary: Improving Pneumococcal Vaccination Rates Following Focused Health Education of Staff and Patients — 1096 participants — p=<.0001
Pneumococcal Infections
Primary: Percentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Vaccination in Participants Aged Between 6 to <18 Years — 21.3; 10.6; 10.6; 0.0…
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination With 20vPnC — 6.3; 7.4; 4.0; 3.3 Percentage of participants
Pneumococcal Infections
Primary: Antibody Concentrations to the 7 Pneumococcal Serotypes Contained in Prevenar — 6.90; 7.16; 7.53; 9.45 μg/mL